Document is current
Any future updates will be listed below
-
Authors
Waks, Adrienne G.
Desai, Neelam V. https://orcid.org/0000-0001-8641-0542
Li, Tianyu
Poorvu, Philip D.
Partridge, Ann H. https://orcid.org/0000-0002-4722-4824
Sinclair, Natalie
Spring, Laura M.
Faggen, Meredith
Constantine, Michael
Metzger, Otto
Alberti, Jillian
Deane, Julia
Rosenberg, Shoshana M.
Frank, Elizabeth
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Krop, Ian E. https://orcid.org/0000-0002-6380-5944
Tung, Nadine M. https://orcid.org/0000-0003-1422-3734
Tayob, Nabihah
King, Tari A.
Mittendorf, Elizabeth A.
Winer, Eric P. https://orcid.org/0000-0002-8819-1723
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
Terri Brodeur Breast Cancer Foundation
Susan G. Komen
- License Information
-
More Information
Article History
Received: 13 August 2021
Accepted: 14 March 2022
First Online: 10 May 2022
Competing interests
: A.G.W.: institutional research support from Genentech, MacroGenics, and Merck. A.H.P.: travel support from Novartis. LMS declares consulting fees from Novartis. O.M.: receives institutional research funding from Abbvie, Genentech/Pfizer, and Roche; honoraria from Roche. S.M.T.: receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Sanofi, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Silverback Therapeutics, G1 Therapeutics, Gilead, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Ellipsis, and Samsung Bioepsis Inc. T.A.K.: speakers honoraria Exact Sciences (formerly Genomic Health); faculty, PrecisCa cancer information services and compensated service for a Global Advisory Board of Besins Healthcare. E.A.M.: institutional research from Genentech/Roche via a SU2C grant; research funding from Exact Sciences and Glaxo SmithKline; has served as an advisor/consultant to AstraZeneca, Bristol-Myers Squibb, Exact Sciences, Genentech/Roche, Lilly, Merck and Sellas. E.P.W.: institutional research funding from Genentech/Roche; consultant for Athenex, Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, Gilead, GSK, Jounce, Lilly, Novartis, Seattle Genetics, Syros, and Zymeworks; scientific advisory board member at Leap Therapeutics; and serves as President-Elect of the American Society of Clinical Oncology (ASCO). All remaining authors have declared no conflicts of interest.
